Quest Diagnostics has signed up to offer a blood test that can help diagnose Alzheimer’s disease, following its FDA clearance ...

Quest will offer the first FDA-approved blood test to help detect Alzheimer’s-related amyloid pathology in patients with ...

The FDA's sign-off on marketing for Fujirebio's test comes years after other blood tests for Alzheimer's have already begun sales, without this kind of approval from the agency.

Fujirebio Diagnostics Receives FDA Breakthrough Device Designation for Lumipulse® G β-Amyloid Ratio (1-42/1-40) Quantitative In Vitro Diagnostic Test ...

The FDA said 91.7% of those tested with the Fujirebio test had the presence of amyloid plaques shown by positron emission tomography (PET) scan or a cerebrospinal fluid (CSF) test result; 97.3% of ...

T he US Food and Drug Administration (FDA) has awarded 510(k) clearance to Fujirebio’s Lumipulse G pTau 217/β-Amyloid 1-42 Plasma Ratio in vitro diagnostic (IVD) test for evaluating amyloid ...

The Food and Drug Administration (FDA) cleared the first blood test on Friday to help diagnose Alzheimer's disease. The test, manufactured by Fujirebio Diagnostics, is for those aged 55 and older ...

Quest Diagnostics (NYSE: DGX), a leader in diagnostic information services, including advanced diagnostics for brain health, today announced it plans to offer laboratory testing based on the ...

The Fujirebio test offering extends this portfolio to include an FDA-cleared option for use in specialized care settings. "Our goal is to advance access to quality and innovative blood-based tests ...

The first Alzheimer's blood test from Fujirebio Diagnostics, now approved by FDA, could help patients with the disease get treatment faster. Skip to Main Content. Manage alerts for this article; ...

Quest Diagnostics to offer US FDA-approved Fujirebio blood test for Alzheimer's disease: Secaucus, New Jersey Friday, July 11, 2025, 14:00 Hrs [IST] Quest Diagnostics, a leader in ...